Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ANIK
  • CUSIP: 03525510
  • Web:
  • Market Cap: $830.96 million
  • Outstanding Shares: 14,658,000
Average Prices:
  • 50 Day Moving Avg: $53.44
  • 200 Day Moving Avg: $47.83
  • 52 Week Range: $41.38 - $57.93
  • Trailing P/E Ratio: 25.18
  • Foreward P/E Ratio: 33.54
  • P/E Growth: 2.59
Sales & Book Value:
  • Annual Revenue: $111.36 million
  • Price / Sales: 7.46
  • Book Value: $16.66 per share
  • Price / Book: 3.40
  • EBIDTA: $56.02 million
  • Net Margins: 33.98%
  • Return on Equity: 19.23%
  • Return on Assets: 17.80%
  • Current Ratio: 14.35%
  • Quick Ratio: 13.04%
  • Average Volume: 98,036 shs.
  • Beta: 1.65
  • Short Ratio: 14.7

Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, July, 26th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.32. The company earned $33.50 million during the quarter, compared to the consensus estimate of $27.20 million. Anika Therapeutics had a return on equity of 19.23% and a net margin of 33.98%. Anika Therapeutics's revenue was up 25.9% on a year-over-year basis. During the same period last year, the company earned $0.57 earnings per share. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Joseph G. Darling, President
  • Charles H. Sherwood Ph.D., Chief Executive Officer, Director
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
  • Dana M. Alexander, Chief Operating Officer
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer
  • Richard Hague, Chief Commercial Officer
  • Joseph Lyon Bower Ph.D., Lead Independent Director
  • Raymond J. Land, Independent Director
  • Glenn R Larsen Ph.D., Independent Director
  • Jeffrey Scott Thompson, Independent Director

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (11.49%), Kayne Anderson Rudnick Investment Management LLC (9.71%), Dimensional Fund Advisors LP (5.99%), Vanguard Group Inc. (5.51%), Bank of New York Mellon Corp (3.35%) and State Street Corp (2.53%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.

Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?

Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Capital Management Corp VA, BTIM Corp., HealthInvest Partners AB, HL Financial Services LLC, Nordea Investment Management AB, OxFORD Asset Management LLP and Russell Investments Group Ltd.. Company insiders that have sold Anika Therapeutics stock in the last year include Charles H Sherwood, Jeffery S Thompson and Joseph I Bower. View Insider Buying and Selling for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Thomson Horstmann & Bryant Inc., Bank of New York Mellon Corp, Dimensional Fund Advisors LP, Kayne Anderson Rudnick Investment Management LLC, AMI Asset Management Corp, Kennedy Capital Management Inc., Stifel Financial Corp and State Street Corp. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $56.69.

MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  143
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Anika Therapeutics (NASDAQ:ANIK)
Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.44N/AView Earnings Details
7/26/2017Q2 2017$0.44$0.76$27.20 million$33.50 millionViewN/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.34$0.42$0.38
Q2 20172$0.42$0.47$0.45
Q3 20172$0.39$0.42$0.41
Q4 20172$0.62$0.62$0.62
Q1 20182$0.32$0.36$0.34
Q2 20181$0.47$0.47$0.47
Q3 20181$0.44$0.44$0.44
Q4 20181$0.50$0.50$0.50
(Data provided by Zacks Investment Research)


Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.47%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2017Charles H SherwoodCEOSell63,799$50.79$3,240,351.21View SEC Filing  
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.75View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
DateHeadline logoViscosupplementation Market By Product, By Region And Segment Forecasts, 2014 - 2025 - September 22 at 1:37 PM logoHead-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers - September 16 at 6:30 PM logoViscosupplementation Market Worth $6.52 Billion by 2025: Grand View Research, Inc. - September 4 at 4:25 PM logoAnika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs - August 28 at 9:02 PM logoAnalyzing Anika Therapeutics (ANIK) and Syros Pharmaceuticals (SYRS) - August 26 at 12:22 AM logoAnika (ANIK) Grows in Orthopedic Medicines on Positive Data - August 15 at 4:52 PM logoETFs with exposure to Anika Therapeutics, Inc. : August 15, 2017 - August 15 at 4:52 PM logoAnika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee - August 7 at 4:46 PM logoZacks Investment Research Upgrades Anika Therapeutics Inc. (ANIK) to Hold - August 2 at 3:46 PM logoNine Chapters Capital Management LLC Buys Pattern Energy Group Inc, Constellation Brands Inc, ... - August 1 at 9:52 PM logoAnika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 - August 1 at 4:51 PM logoInsider Selling: Anika Therapeutics Inc. (NASDAQ:ANIK) CEO Sells 63,799 Shares of Stock - July 31 at 7:29 PM logoHead to Head Contrast: Tokai Pharmaceuticals (NVUS) and Anika Therapeutics (ANIK) - July 28 at 12:33 PM logoGainers & Losers Of July 27: CAPR, ANIK, MMSI, AZN, TTPH, AGEN... - July 28 at 1:43 AM logoEdited Transcript of ANIK earnings conference call or presentation 27-Jul-17 1:00pm GMT - July 28 at 1:43 AM logoAnika Announces Appointment of Joseph Darling as President - July 27 at 3:35 PM logoAnika Therapeutics Inc. (NASDAQ:ANIK) Issues Earnings Results - July 27 at 12:39 PM logoAnika posts 2Q profit - July 26 at 9:28 PM logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : July 26, 2017 - July 26 at 4:27 PM logoAnika Reports Strong Second Quarter 2017 Financial Results - July 26 at 4:27 PM logoAnika Announces Regulatory Approval for MONOVISC® in India for the Treatment of Pain Associated with Osteoarthritis of All Synovial Joints - July 24 at 6:15 PM logoCritical Analysis: Anika Therapeutics (NASDAQ:ANIK) & KalVista Pharmaceuticals (KALV) - July 24 at 4:06 PM logoZacks: Brokerages Anticipate Anika Therapeutics Inc. (ANIK) Will Announce Earnings of $0.44 Per Share - July 21 at 10:12 AM logoZacks: Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Analysts - July 21 at 9:18 AM logoThe Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics - July 18 at 5:22 PM logoAnika Therapeutics Inc. (ANIK) Set to Announce Earnings on Tuesday - July 18 at 8:16 AM logoBRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc - July 17 at 9:19 PM logoAnika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC - July 17 at 4:16 PM logoAnika pays former medical chief $350K to thwart possible lawsuit - July 17 at 12:36 PM logoAnika Therapeutics (ANIK) Presents At Singular Summer Solstice Conference - Slideshow - July 13 at 4:39 PM logoAnika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017 - July 12 at 4:24 PM logoAnika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26 - July 12 at 4:24 PM logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : July 11, 2017 - July 11 at 5:08 PM logoNew Strong Sell Stocks for July 11th - July 11 at 5:07 PM logoETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017 - July 11 at 5:07 PM logoResearch Analysts Offer Predictions for Anika Therapeutics Inc.'s Q2 2017 Earnings (ANIK) - July 10 at 7:36 AM logoCharles H. Sherwood Sells 14,201 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) Stock - July 6 at 7:22 PM logoAnika to Present at the Singular Research Summer Solstice Conference on July 13, 2017 - July 6 at 5:10 PM logoZacks Investment Research Upgrades Anika Therapeutics Inc. (ANIK) to "Hold" - July 5 at 4:26 PM logoBrokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.49 EPS - June 28 at 10:28 AM logoFacial Injectables Market to Reach $17.2 Billion by 2025 - Fueled by Advancements in Facial Rejuvenation Procedures - Research and Markets - June 24 at 2:12 AM logoFacial Injectables Market is expected to reach USD 17.2 billion by 2025 - June 20 at 9:09 PM logoHere Comes a Big Breakout For Alibaba - June 20 at 4:08 PM logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : June 19, 2017 - June 19 at 3:39 PM logoETFs with exposure to Anika Therapeutics, Inc. : June 14, 2017 - June 14 at 3:38 PM logoFacial Injectables Market Size Worth $17.2 Billion By 2025: Grand View Research, Inc. - June 13 at 1:04 PM logoETFs with exposure to Anika Therapeutics, Inc. : June 2, 2017 - June 2 at 4:47 PM logoAnika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017 - June 1 at 3:46 PM logoAnika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress - May 30 at 8:41 PM logoAnika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis - May 25 at 4:05 PM



Anika Therapeutics (ANIK) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff